
Geum-Youn Gwak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5484144/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 1383-1391.e6.	1.3	371
2	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut, 2014, 63, 1943-1950.	12.1	149
3	Lowâ€level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017, 66, 335-343.	7.3	144
4	Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut, 2017, 66, 323-329.	12.1	125
5	Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. Journal of Hepatology, 2017, 67, 1274-1280.	3.7	120
6	Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance. Radiology, 2015, 276, 274-285.	7.3	113
7	Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients with low viral load. Hepatology, 2015, 62, 694-701.	7.3	106
8	Ultrasonographically Detected Non-Alcoholic Fatty Liver Disease Is an Independent Predictor for Identifying Patients With Insulin Resistance in Non-Obese, Non-Diabetic Middle-Aged Asian Adults. American Journal of Gastroenterology, 2012, 107, 561-567.	0.4	104
9	Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. Gastroenterology, 2016, 151, 481-488.e1.	1.3	95
10	High-Mobility Group Box 1 Is Dispensable for Autophagy, Mitochondrial Quality Control, and Organ Function InÁVivo. Cell Metabolism, 2014, 19, 539-547.	16.2	82
11	Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Scientific Reports, 2018, 8, 4718.	3.3	68
12	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Medicine, 2022, 14, 1.	8.2	68
13	Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Hepatology, 2020, 71, 2023-2032.	7.3	66
14	Nonâ€alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 833-839.	2.8	66
15	Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. Liver International, 2018, 38, 1442-1448.	3.9	65
16	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS ONE, 2019, 14, e0210730.	2.5	64
17	Clinical Features, Image Findings, and Prognosis of Inflammatory Pseudotumor of the Liver: A Multicenter Experience of 45 Cases. Gut and Liver, 2014, 8, 58-63.	2.9	64
18	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunology, Immunotherapy, 2019, 68, 23-32.	4.2	62

#	Article	IF	CITATIONS
19	Nonâ€alcoholic fatty liver diseases and risk of colorectal neoplasia. Alimentary Pharmacology and Therapeutics, 2017, 45, 345-353.	3.7	54
20	The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver International, 2014, 34, 795-801.	3.9	51
21	The recommended treatment algorithms of the <scp>BCLC</scp> and <scp>HKLC</scp> staging systems: does following these always improve survival rates for <scp>HCC</scp> patients?. Liver International, 2016, 36, 1490-1497.	3.9	51
22	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. Journal of Hepatology, 2015, 62, 1112-1121.	3.7	50
23	Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort. PLoS ONE, 2014, 9, e112184.	2.5	49
24	Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS ONE, 2016, 11, e0154986.	2.5	48
25	The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. Journal of Clinical Lipidology, 2016, 10, 289-298.	1.5	47
26	Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World Journal of Gastroenterology, 2012, 18, 679.	3.3	47
27	Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. European Journal of Endocrinology, 2019, 181, 185-192.	3.7	46
28	Liver Function Assessment Using Albumin–Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Digestive Diseases and Sciences, 2017, 62, 3235-3242.	2.3	44
29	Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread. PLoS ONE, 2015, 10, e0124434.	2.5	43
30	Nonâ€invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with lowâ€level viremia. Liver International, 2018, 38, 68-75.	3.9	42
31	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clinical and Molecular Hepatology, 2016, 22, 250-258.	8.9	42
32	Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clinical and Molecular Hepatology, 2020, 26, 516-528.	8.9	42
33	Monotherapy with tenofovir disoproxil fumarate for multiple drugâ€resistant chronic hepatitis B: 3â€year trial. Hepatology, 2017, 66, 772-783.	7.3	37
34	Disease progression and the risk factor analysis for chronic hepatitis C. Liver International, 2008, 28, 1363-1369.	3.9	35
35	Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. Clinical Gastroenterology and Hepatology, 2022, 20, 427-437.e5.	4.4	33
36	Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut, 2016, 65, 1721-1732.	12.1	31

#	Article	IF	CITATIONS
37	Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. Liver Cancer, 2021, 10, 52-62.	7.7	30
38	Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. Liver International, 2012, 32, 937-944.	3.9	29
39	Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. Atherosclerosis, 2014, 234, 270-275.	0.8	29
40	Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. Journal of Hepatology, 2019, 71, 35-44.	3.7	29
41	Transcatheter arterial chemoembolization and radiation therapy for treatment-naÃ ⁻ ve patients with locally advanced hepatocellular carcinoma. Radiation Oncology Journal, 2014, 32, 14.	1.5	28
42	Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. Journal of Viral Hepatitis, 2020, 27, 896-903.	2.0	26
43	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget, 2016, 7, 47794-47807.	1.8	24
44	Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. European Radiology, 2016, 26, 3437-3446.	4.5	24
45	Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study. Hepatology, 2022, 76, 1746-1754.	7.3	24
46	Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1100-1106.	2.8	23
47	Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Digestive Diseases and Sciences, 2018, 63, 1062-1071.	2.3	23
48	Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. Clinical and Molecular Hepatology, 2016, 22, 477-486.	8.9	23
49	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. Gut and Liver, 2017, 11, 528-534.	2.9	22
50	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. Liver International, 2015, 35, 2363-2369.	3.9	21
51	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Annals of Surgical Treatment and Research, 2020, 99, 238.	1.0	20
52	Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean Journal of Internal Medicine, 2015, 30, 32.	1.7	19
53	Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. Annals of Surgery, 2018, 268, 1043-1050.	4.2	18
54	Long-term real-world entecavir therapy in treatment-naÃ ⁻ ve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean Journal of Internal Medicine, 2017, 32, 636-646.	1.7	17

#	Article	IF	CITATIONS
55	Hepatitis B virus DNA levels and overall survival in hepatitis Bâ€related hepatocellular carcinoma patients with lowâ€level viremia. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2028-2035.	2.8	17
56	Percutaneous Radiofrequency Ablation of Small (1–2 cm) Hepatocellular Carcinomas Inconspicuous on B-Mode Ultrasonographic Imaging: Usefulness of Combined Fusion Imaging with MRI and Contrast-Enhanced Ultrasonography. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-9.	1.9	16
57	Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. Radiation Oncology Journal, 2018, 36, 25-34.	1.5	16
58	Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut and Liver, 2016, 10, 939-947.	2.9	15
59	Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. World Journal of Gastroenterology, 2016, 22, 3785.	3.3	15
60	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatology International, 2021, 15, 892-900.	4.2	15
61	Laparoscopic Liver Resection of Hepatocellular Carcinoma with a Tumor Size Larger Than 5 cm: Review of 45 Cases in a Tertiary Institution. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2017, 27, 799-803.	1.0	14
62	Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. International Journal of Epidemiology, 2020, 49, 1562-1571.	1.9	14
63	Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, e529-e534.	1.6	14
64	Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. Digestive and Liver Disease, 2021, 53, 1004-1010.	0.9	14
65	Metabolically-healthy obesity is associated with higher prevalence of colorectal adenoma. PLoS ONE, 2017, 12, e0179480.	2.5	14
66	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. Gut and Liver, 2016, 10, 295.	2.9	14
67	Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut and Liver, 2016, 10, 796-802.	2.9	14
68	Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study. American Journal of Gastroenterology, 2021, 116, 329-335.	0.4	14
69	Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2016, 61, 3354-3362.	2.3	13
70	Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. European Journal of Gastroenterology and Hepatology, 2018, 30, 1447-1452.	1.6	13
71	Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study. Journal of Korean Medical Science, 2018, 33, e264.	2.5	13
72	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. Journal of Viral Hepatitis, 2021, 28, 1392-1399.	2.0	13

#	Article	IF	CITATIONS
73	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clinical and Molecular Hepatology, 2017, 23, 42-50.	8.9	13
74	Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. Scientific Reports, 2022, 12, 7647.	3.3	13
75	The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding. Clinical and Molecular Hepatology, 2014, 20, 283.	8.9	12
76	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. Journal of Korean Medical Science, 2015, 30, 1618.	2.5	12
77	Nonâ€alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1053-1058.	2.8	12
78	Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. PLoS ONE, 2019, 14, e0213547.	2.5	12
79	Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase Il trial. Oncotarget, 2017, 8, 52651-52664.	1.8	12
80	Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. Hepatology International, 2013, 7, 1010-1018.	4.2	11
81	Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. BMC Cancer, 2019, 19, 286.	2.6	11
82	Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. Korean Journal of Internal Medicine, 2020, 35, 65-78.	1.7	11
83	Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. Digestive Diseases and Sciences, 2022, 67, 4565-4573.	2.3	11
84	The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nationâ€wide Cohort Study. Hepatology, 2021, 74, 2988-2997.	7.3	10
85	Occult hepatitis B virus infection in chronic hemodialysis patients in Korea. Hepato-Gastroenterology, 2008, 55, 1721-4.	0.5	10
86	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. Clinical and Translational Gastroenterology, 2021, 12, e00290.	2.5	9
87	Nonlinear tumor evolution from dysplastic nodules to hepatocellular carcinoma. Oncotarget, 2017, 8, 2076-2082.	1.8	8
88	Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigenâ€negative, core antibodyâ€positive recipients. Journal of Viral Hepatitis, 2020, 27, 739-746.	2.0	8
89	Survival in untreated hepatocellular carcinoma: A national cohort study. PLoS ONE, 2021, 16, e0246143.	2.5	8
90	Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. Clinical and Molecular Hepatology, 2015, 21, 232.	8.9	7

#	Article	IF	CITATIONS
91	Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis. Medicine (United States), 2016, 95, e2578.	1.0	6
92	Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial. International Journal of Hyperthermia, 2016, 32, 331-338.	2.5	6
93	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Medical Journal, 2021, 62, 12.	2.2	6
94	Clinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis. Korean Journal of Internal Medicine, 2020, 35, 215-221.	1.7	6
95	Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study. BMC Medicine, 2022, 20, 18.	5.5	6
96	Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. Scandinavian Journal of Gastroenterology, 2018, 53, 727-733.	1.5	5
97	Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. Digestive Diseases and Sciences, 2021, 66, 2816-2825.	2.3	5
98	Longâ€ŧerm hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients—Functional cure unlikely. Journal of Viral Hepatitis, 2020, 27, 951-954.	2.0	5
99	Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. PLoS ONE, 2015, 10, e0144777.	2.5	5
100	Clinical Impact of the Development of YMDD Mutants in Hepatitis B Virus-Associated Glomerulonephritis. Hepato-Gastroenterology, 2011, 58, 1291-1295.	0.5	5
101	The correlation of hepatitis B virus pre-S mutation with mitochondrial D-loop mutations and common deletions in hepatocellular carcinoma. Hepato-Gastroenterology, 2011, 58, 522-8.	0.5	5
102	Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. Korean Journal of Internal Medicine, 2022, 37, 1082-1087.	1.7	5
103	A comparison of clevudine and entecavir for treatment-naÃ ⁻ ve patients with chronic hepatitis B: results after 2Âyears of treatment. Hepatology International, 2013, 7, 106-110.	4.2	4
104	Relationship of Liver Stiffness and Controlled Attenuation Parameter Measured by Transient Elastography with Diabetes Mellitus in Patients with Chronic Liver Disease. Journal of Korean Medical Science, 2014, 29, 1113.	2.5	4
105	Inclusive Quantification Assay of Serum Desâ€Î³â€Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. Hepatology Communications, 2021, 5, 1767-1783.	4.3	4
106	Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein. Clinical and Molecular Hepatology, 2015, 21, 393.	8.9	4
107	The correlation of hepatitis B virus pre-S mutation with cellular oxidative DNA damage in hepatocellular carcinoma. Hepato-Gastroenterology, 2008, 55, 2028-32.	0.5	4
108	Weight Change and Development of Subclinical Carotid Atherosclerosis Among Metabolically Healthy Adults: A Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e410-e416.	3.6	3

#	Article	IF	CITATIONS
109	Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels. World Journal of Gastroenterology, 2013, 19, 2256.	3.3	3
110	Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scandinavian Journal of Gastroenterology, 2021, , 1-8.	1.5	3
111	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. Digestive and Liver Disease, 2021, 53, 210-215.	0.9	2
112	Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea. Korean Journal of Transplantation, 2021, 35, 24-32.	0.1	2
113	Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. Digestive Diseases and Sciences, 2015, 60, 3794-3800.	2.3	1
114	Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. PLoS ONE, 2021, 16, e0255624.	2.5	1
115	Letter: <i>Helicobacter pylori</i> -related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 577-578.	3.7	0
116	Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. Transplantation Proceedings, 2020, 52, 881-888.	0.6	0
117	Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. Scandinavian Journal of Gastroenterology, 2021, 56, 274-280.	1.5	0
118	Comparison of Mac-2 Binding Protein Glycosylation Isomer, Fibroscan, and Other Fibrosis Markers for Assessing Liver Cirrhosis in Patients with Chronic Hepatitis B Virus-mediated Hepatocellular Carcinoma. Laboratory Medicine Online, 2020, 10, 109.	0.2	0
119	Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. Scandinavian Journal of Gastroenterology, 0, , 1-8.	1.5	0